Phoenix PharmaLabs (PPL) is a preclinical drug discovery company developing, potent, safe, non-addictive treatment for pain and addiction. PPL’s lead drug, PPL-103, has demonstrated in extensive animal studies that it is a very potent painkiller (10x morphine), is non-addictive, does not produce physical dependence / withdrawal, does not cause death from overdose (even at 350x the analgesic dose) and causes no constipation. It has also demonstrated effectiveness in treating opioid and cocaine addiction.
Several leading pharma companies have expressed interest in licensing PPL-103 once it has entered human clinical trials. PPL plans to advance PPL-103 through Phase I, then to Proof of Concept, at which point PPL will enter into negotiations to license PPL-103.
We thoroughly reviewed all drugs in development worldwide that had the potential to be as effective as PPL-103 in treating severe pain while being non-addictive and safe. We found only one - and we just acquired all rights to it.
Several leading pharma companies have expressed interest in licensing PPL-103 once it has entered human clinical trials. PPL plans to advance PPL-103 through Phase I, then to Proof of Concept, at which point PPL will enter into negotiations to license PPL-103.
We thoroughly reviewed all drugs in development worldwide that had the potential to be as effective as PPL-103 in treating severe pain while being non-addictive and safe. We found only one - and we just acquired all rights to it.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Utah
Company HQ Country:
United States
Year Founded:
2002
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
PPL-103
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
